SHANGHAI, May 3, 2017 /PRNewswire/ -- IMPACT Therapeutics, Inc. (IMPACT) announced that CFDA granted approval to its IND application of IMP4297, a potential best-in-class PARP inhibitor, in January 2017. The company dosed the first patient in its Australian Phase I trial in February 2017, and has since initiated IMP4297 Phase I clinical trial in China.
Dr. Edward Tian, CEO of IMPACT, is looking forward to the IMP4297 clinical trials in China. He said: "It took us about one year to obtain the CFDA approval from the time of our IND submission. The reforms within CFDA have shortened R&D cycle and reduced R&D cost. More importantly, given the CFDA's accelerated efforts to bring new drugs to market, Chinese patients should have access to innovative drugs in a more timely manner."
Dr. Sui Xiong Cai, SVP and CTO of IMPACT, is optimistic about the company's projects. He stated: "IMPACT has a highly experienced management team, which is important for the successful development of our products. IMP4297 is a high potency PARP inhibitor discovered and developed in China. It has the potential to demonstrate better clinical efficacies than the currently marketed PARP inhibitors, and to be developed into a best-in-class new drug."
"IMP4297 has excellent pharmacological activity and high selectivity. Hopefully these preclinical advantages will be confirmed in clinical trials, so that we could share the good results with you soon," stated Dr. Limin Wen, VP and CMO.
About IMPACT Therapeutics
Funded by venture capital and based in China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and "best-in-class" therapeutics to treat cancer and other life-threatening diseases. IMPACT has a highly experienced management team. IMPACT has successfully established an effective research and business model, using unique method for the discovery and development of novel anti-cancer drugs. IMPACT has several anti-tumor drug projects in the preclinical and clinical stage. For more information, please visit the company's web site www.impacttherapeutics.com.
SOURCE Impact Therapeutics